STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [Form 4] MapLight Therapeutics, Inc. Insider Trading Activity

MapLight Therapeutics (MPLT) director granted RSUs and 29,804-share stock option

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics director Babler Martin received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units and a stock option for 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share.

The RSUs and option were granted under the 2025 Equity Incentive Plan and will vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service. Following these grants, Martin holds 7,864 shares of Voting Common Stock directly and the newly granted option covering 29,804 underlying shares.

Positive

  • None.

Negative

  • None.
Insider Babler Martin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 29,804 $0.00 --
Grant/Award Voting Common Stock 7,864 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 29,804 shares (Direct, null); Voting Common Stock — 7,864 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
RSUs granted 7,864 units Restricted stock units granted June 23, 2026
Stock options granted 29,804 options Stock option covering Voting Common Stock
Option exercise price $28.64 per share Conversion/exercise price for stock option
Shares underlying option 29,804 shares Underlying Voting Common Stock for option
Shares held after RSU grant 7,864 shares Total Voting Common Stock after transaction
Option expiration June 22, 2036 Expiration date of stock option grant
restricted stock units financial
"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2025 Equity Incentive Plan financial
"granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan")"
Continuous Service financial
"subject to the Continuous Service (as defined in the Plan) of the Reporting Person"
non-employee director compensation policy financial
"This grant was made pursuant to the Issuer's non-employee director compensation policy."
Stock Option (right to buy) financial
"Represents a stock option granted pursuant to the Plan."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Babler Martin
(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock06/23/2026A7,864(1)A$0(2)7,864D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$28.6406/23/2026A29,804 (3)06/22/2036Voting Common Stock29,804$029,804D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
3. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
/s/ Kristopher L. Hanson, Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did MapLight Therapeutics (MPLT) director Babler Martin receive in this Form 4?

Babler Martin received equity-based compensation consisting of 7,864 restricted stock units and a stock option for 29,804 shares. Both awards were granted under MapLight Therapeutics’ 2025 Equity Incentive Plan as part of its non-employee director compensation policy.

How do the RSUs granted to Babler Martin by MapLight Therapeutics (MPLT) vest?

The 7,864 restricted stock units vest in three equal annual installments starting June 23, 2027. Vesting is conditioned on Babler Martin’s Continuous Service with MapLight Therapeutics on each applicable vesting date, as defined in the company’s 2025 Equity Incentive Plan.

What are the key terms of Babler Martin’s new stock option at MapLight Therapeutics (MPLT)?

The stock option covers 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share. It vests in three equal annual installments beginning June 23, 2027, subject to Babler Martin’s Continuous Service with MapLight Therapeutics on each vesting date.

How many MapLight Therapeutics (MPLT) shares does Babler Martin hold after these grants?

After these awards, Babler Martin directly holds 7,864 shares of Voting Common Stock. He also holds a newly granted stock option covering 29,804 underlying shares, which vest over time, reflecting equity compensation rather than an open-market purchase.

Are Babler Martin’s new equity awards at MapLight Therapeutics (MPLT) open-market purchases or compensation grants?

These transactions are compensation grants, not open-market purchases. The Form 4 identifies them with transaction code “A” as awards under the 2025 Equity Incentive Plan and the company’s non-employee director compensation policy, with no cash price paid at grant.

When will Babler Martin’s RSUs and options from MapLight Therapeutics (MPLT) fully vest?

Both the 7,864 RSUs and the 29,804-share stock option vest in three equal annual tranches starting June 23, 2027. Full vesting occurs after three years, assuming Babler Martin continues to satisfy the Continuous Service requirement on each annual vesting date.